Loading...
Market
How will Ascendis Pharma's stock react to the next update on TransCon CNP by March 31, 2025?
2
Resolution / Starting Odds
Stock increases by more than 10% • 25%
Stock increases by 5-10% • 25%
Stock changes by less than 5% • 25%
Stock decreases • 25%
NASDAQ or official stock market data
Story
Ascendis Pharma's TransCon CNP Achieves Primary Objective in ApproaCH Trial, Stock Surges 19.9%
Sep 16, 2024, 12:02 PM
Ascendis Pharma (ASND) announced that its pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) achieved its primary objective, demonstrating a superior annual growth velocity (AGV) compared to placebo. The trial showed a least squares mean treatment difference of 1.49 cm/year at Week 52, with children aged 5-11 years showing a change from baseline AGV superior to placebo with a least squares mean treatment difference of 1.78 cm/year at Week 52. Following the announcement, Ascendis Pharma's stock surged by 19.9% in pre-market trading. This development poses a competitive challenge to Biomarin's Voxzogo, which was previously considered superior. Ascendis Pharma's stock was up +17% in pre-market trading, while Biomarin's stock dropped by 15%. The trial was double-blind and placebo-controlled.
View original story
Similar markets
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
Above 30% • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Merck • 25%
No acquisition • 25%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
Increase by more than 5% • 25%
Increase by 0-5% • 25%
Decrease by 0-5% • 25%
Decrease by more than 5% • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
No Results • 25%
Stock price increases by more than 10% • 25%
Stock price remains within +/- 10% range • 25%
Stock price decreases by more than 10% • 25%
Stock price fluctuates but ends within +/- 5% range • 25%
Takeda • 25%
Amgen • 25%
Novo Nordisk • 25%
Other • 25%